Fiera Capital Corp Reduces Stock Holdings in Danaher Co. (NYSE:DHR)

Fiera Capital Corp cut its holdings in Danaher Co. (NYSE:DHR - Free Report) by 8.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 219,589 shares of the conglomerate's stock after selling 20,807 shares during the quarter. Fiera Capital Corp's holdings in Danaher were worth $50,800,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in DHR. Banco Santander S.A. acquired a new stake in Danaher during the 3rd quarter worth about $683,000. Cary Street Partners Investment Advisory LLC boosted its position in Danaher by 20.2% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate's stock valued at $2,112,000 after buying an additional 1,533 shares during the last quarter. First Citizens Bank & Trust Co. increased its holdings in Danaher by 0.6% in the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate's stock worth $6,156,000 after buying an additional 149 shares during the period. Cercano Management LLC raised its position in Danaher by 11.4% during the 4th quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate's stock worth $46,862,000 after buying an additional 20,715 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in Danaher by 48.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate's stock valued at $68,707,000 after acquiring an additional 96,395 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Price Performance

NYSE:DHR traded up $1.38 during trading hours on Thursday, reaching $264.84. 3,437,222 shares of the company were exchanged, compared to its average volume of 2,705,707. The stock's 50-day moving average is $248.28 and its 200-day moving average is $235.43. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $265.36. The firm has a market cap of $196.16 billion, a PE ratio of 44.62, a price-to-earnings-growth ratio of 3.87 and a beta of 0.83. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the prior year, the firm earned $2.36 EPS. The company's revenue for the quarter was down 2.6% on a year-over-year basis. On average, sell-side analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date is Friday, June 28th. Danaher's dividend payout ratio is presently 18.31%.

Analyst Upgrades and Downgrades

DHR has been the subject of several recent research reports. Bank of America raised their target price on shares of Danaher from $258.00 to $270.00 and gave the stock a "neutral" rating in a report on Wednesday, April 24th. StockNews.com cut Danaher from a "buy" rating to a "hold" rating in a report on Wednesday, January 31st. KeyCorp upped their target price on Danaher from $260.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, February 1st. Citigroup lifted their price target on Danaher from $280.00 to $290.00 and gave the company a "buy" rating in a research report on Wednesday, April 24th. Finally, Robert W. Baird raised their price objective on shares of Danaher from $259.00 to $271.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Danaher has a consensus rating of "Moderate Buy" and a consensus target price of $267.31.

Insider Buying and Selling

In other Danaher news, Director Alan G. Spoon sold 708 shares of the firm's stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares in the company, valued at $9,601,704. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Alan G. Spoon sold 708 shares of the company's stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares of the company's stock, valued at $28,304,483.16. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 163,535 shares of company stock worth $41,137,156. 10.90% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.